• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. 重型血友病A伴高滴度抑制物的免疫耐受诱导治疗一例并文献复习

重型血友病A伴高滴度抑制物的免疫耐受诱导治疗一例并文献复习

来源 :第十五届全国实验血液学学术会议 | 被引量 : 0次 | 上传用户：gaolch003
【摘 要】
：
在血友病A替代治疗过程中FⅧ抑制物的生成是最严重的并发症.免疫耐受诱导治疗(Immune tolerance induction,ITI)可有效清除抑制物.本文报道l例高滴度抑制物血友病A患者,低剂量ITI方案治疗6个月后FⅧ抑制物从高滴度下降为低滴度(范围0.45-3.1BU/ml),输注FⅧ后回收率＞66％,记忆反应消失.随访47个月患者FⅧ抑制物仍为低滴度,加大FⅧ剂量治疗出血事件有效,是国
【作 者】
：
黄顺桦 孙竞 黄顺桦 秦芳梅 刘阳 
【机 构】
：
南方医科大学南方医院
【出 处】
：
第十五届全国实验血液学学术会议
【发表日期】
：
2015年3期
【关键词】
：
血友病A 抑制物 免疫耐受 
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　在血友病A替代治疗过程中FⅧ抑制物的生成是最严重的并发症.免疫耐受诱导治疗(Immune tolerance induction,ITI)可有效清除抑制物.本文报道l例高滴度抑制物血友病A患者,低剂量ITI方案治疗6个月后FⅧ抑制物从高滴度下降为低滴度(范围0.45-3.1BU/ml),输注FⅧ后回收率＞66％,记忆反应消失.随访47个月患者FⅧ抑制物仍为低滴度,加大FⅧ剂量治疗出血事件有效,是国内在危及生命出血时机紧急启动ITI,且以低剂量和较低费用获得部分成功效果的首例成功报告.根据此案例积累ITI经验,进一步探索符合中国国情的ITI方案.
其他文献
Idarubicin compared to other anthracyclines for newly diagnosed acute myeloid leukaemia
Background and Objective There is no evidence that would definitively prove the superiority of IDA versus other anthracyclines in induction therapy of newly diagnosed acute myeloid leukemia (AML).We p
会议
Idarubicinacute myeloid leukaemia
High doses of daunorubicin during induction therapy of newly diagnosed acute myeloid leukemia: a sys
The right dose of daunorubicin (DNR) for the treatment of newly diagnosed acute myeloid leukemia (AML)is uncertain.Previous trials have shown conflicting results concerning the efficacy of high or low
会议
High doses of daunorubicininduction therapyacute myeloid leukemia
Cyclosporine A versus Tacrolimus as Immunosuppressive Therapy after Allogeneic Hematopoietic Stem Ce
Background and Objective Cyclosporine A (CsA) has been used as immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation (HSCT) for about 30 years.Recently, Tacrolimus (FK506)
会议
Cyclosporine ATacrolimusAllogeneic Hematopoietic Stem Cell Transplantation
High-dose cytarabine for consolidation therapy of acute myeloid leukemia in first complete remission
Background New evidence has questioned the role of high-dose cytarabine (HDAC) in consolidation therapy of acute myeloid leukemia (AML) in first complete remission (CR1).We performed a meta-analysis t
会议
High-dose cytarabineconsolidation therapyacute myeloid leukemia
Co-transplantation with mesenchymal stem cells expressing a SDF-1/HOXB4 fusion protein markedly impr
Introduction Mesenchymal stem cells (MSCs) contribute to the engraftment of transplanted hematopoietic stem cells (HSCs).MSCs also accelerate hematological recovery by secreting SDF-1 and enabling HSC
会议
SDF-1/HOXB4hematopoietic stem cellirradiated mice
The effects of allogeneic stem cell transplantation with matched sibling donor versus autologous ste
Background Multiple myeloma (MM) is a malignant proliferative disease which is characterized by excessive proliferation of abnormal plasma cell originated from post-germinal-center B cells.The choice
会议
The effects of allogeneic stem cell transplantation with matched sibling donor v
Decreased level of cytotoxic T lymphocyte antigen-4 (CTLA-4) in patients with acute immune thrombocy
Objective Previously, we demonstrated the importance ofT-cell immune response cDNA 7 (TIRC7) in acute i mmune thrombocytopenia (ITP).As the downstream molecule of TIRC7, cytotoxic T lymphocyte antigen
会议
acute immune thrombocytopenia(ITP)cytotoxic T lymphocyte antigen-4(CTLA-4)immu
Comparison of Total Body Irradiation with Busulfan/Cyclophosphamide on the Development of Hepatic Ve
Aims To evaluate and compare the effect of total body irradiation (TBI) with busulfan/cyclophosphamide (BU/CY) as conditioning regimen on the development of hepatic veno-occlusive disease (HVOD) occur
会议
Hematopoietic Stem Cell TransplantationHepatic Veno-Occlusive Disease
Dexamethasone down-regulates Th1 cells by modulating T-cell immune response cDNA7 in acute immune th
Objective T-cell immune response cDNA 7(TIRC7) has been identified and demonstrated to be essential in T cell activation.However, the role of TIRC7 in acute immune thrombocytopenia (ITP) re mains poor
会议
Dexamethasoneacute immune thrombocytopeniaTh1 cellsT-cell immune response cDN
Retuximab successfully treat unicentric Castleman disease complicated by paraneoplastic pemphigus an
Introduction Castleman disease(CD) was named after Dr Benjamin Castleman when he described 13 cases ofmediastinal lymphnode swelling in the year 1956 and is characterized by non-clonal B cell prolifer
会议
RituximabCastleman diseaseparaneoplastic pemphigusbronchitis obsterans